Related Experiment Video
Updated: Sep 13, 2025

Author Spotlight: Self-Assessment Protocol for Predicting Psoriatic Arthritis in Psoriasis Patients
Published on: March 1, 2024
Understanding difficult-to-treat psoriatic arthritis: Data from the Rheumatic Diseases Portuguese Registry
Catarina Abreu1, Vanessa Fraga1, Sara Dias Rodrigues2
1Rheumatology Department, Hospital Garcia de Orta, Unidade Local de Saúde Almada-Seixal, Avenida Torrado da Silva, 2805-267 Almada, Portugal.
Objectives:
To estimate the proportion and identify predictors of difficult-to-treat (D2T) psoriatic arthritis (PsA).
Methods:
A multicentre observational retrospective study was conducted with patients registered in the Rheumatic Diseases Portuguese Registry (Reuma.pt). Two different definitions were used to classify D2T PsA. The first criterion (treatment failure) is defined by the failure of≥2 b/tsDMARDs (first definition) or≥3 b/tsDMARDs (second definition), both with different MoAs; and the second criterion is defined by the presence of signs suggestive of active/progressive disease.
Results:
In total, 1873 patients were included, of whom 3.7% (n=70) were classified as having D2T PsA according to the first definition and 0.9% (n=17) as having D2T PsA according to the second definition. D2T PsA was associated with a younger age at symptom onset (37.5±11.0 vs. 41.4±12.8; P<0.01) and at diagnosis (40.7±10.5 vs. 44.7±12.3; P<0.01), polyarticular phenotype (77.6% vs. 53.6%; P<0.001), depression (10.9% vs. 5%; P<0.05), and enthesitis (47.1% vs. 33.5%; P<0.05) and lower body mass index (26.5[6.1] vs. 27.7[6.1]; P<0.01). D2T PsA patients presented with higher tender (13.4[14.5] vs. 6[8]; P<0.001) and swollen joint counts (9[9] vs. 4[6]; P<0.001) and higher DAPSA (38.2[31.6] vs. 25.4[15.6]; P<0.001) at baseline. Polyarticular disease (OR: 3.09), increased baseline swollen joint count (OR: 1.12), and treatment duration on the first b/tsDMARDs (P<0.01) were predictors of D2T PsA.
Conclusion:
D2T PsA proportions varied between 0.9% and 3.7%. D2T PsA patients had higher disease activity scores before the initiation of their first b/tsDMARDs and higher rates of treatment discontinuation.
More Related Videos
Related Concept Videos
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease I: Introduction
Rheumatic Heart Disease III: Medical Management
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Peripheral Artery Disease I: Introduction

